CD274 and neoplasm: The programmed cell death factor 1 (PD-1) / programmed cell death ligand 1 (PD-L1) inhibitor, as classical immune checkpoint inhibitors (ICIs), have achieved good clinical outcomes in various solid tumors and are considered to be a promising tumor treatment strategy.